Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Inclusion criteria * Age ≥ 16 years * Newly diagnosed locally advanced or metastatic primary lung cancer (histologically/ cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT * Ambulatory (receiving outpatient SACT) Exclusion criteria * Hypersensitivity to apixaban or to any of the listed SmPC excipients * Active clinically significant bleeding * Lesion or condition considered a significant risk factor for major bleeding * Hepatic disease associated with impaired synthetic function * Platelet count \< 50 x 109 /L * Elevated liver enzymes ALT/AST \> 2 x ULN or total bilirubin ≥ 1.5 x ULN * Renal failure (creatinine clearance \< 15ml/min) * Weight \< 40kg * Estimated life expectancy \< 6 months * Continuous anticoagulation (e.g., unfractionated heparin, low molecular weight heparins, heparin derivatives and oral anticoagulants) for other medical conditions * The usage of medications contraindicated with apixaban * Pregnancy * Breast feeding * Judgement by the Investigator that the participant is unsuitable to participate in the trial and the participant is unlikely to comply with trial procedures, restrictions and requirements * Inability to consent * Receiving SACT for potentially resectable / resectable lung cancer as part of neo-adjuvant or adjuvant treatment * SACT with significant potential DDI with apixaban (section 7.2.3)